Cargando…

Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors

Aim: The aim of this study was to demonstrate the utility of T-Cell receptor beta (TCRβ) sequencing as a robust method for assessing T-cell repertoire changes in donors with non-small cell lung cancer (NSCLC). We further demonstrated the use of the assay by monitoring repertoire modulation in a defi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Leisa P., Tjoa, Benjamin A., Mellert, Hestia, Pestano, Gary A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992474/
https://www.ncbi.nlm.nih.gov/pubmed/35582444
http://dx.doi.org/10.20517/cdr.2020.07
_version_ 1784683737401786368
author Jackson, Leisa P.
Tjoa, Benjamin A.
Mellert, Hestia
Pestano, Gary A.
author_facet Jackson, Leisa P.
Tjoa, Benjamin A.
Mellert, Hestia
Pestano, Gary A.
author_sort Jackson, Leisa P.
collection PubMed
description Aim: The aim of this study was to demonstrate the utility of T-Cell receptor beta (TCRβ) sequencing as a robust method for assessing T-cell repertoire changes in donors with non-small cell lung cancer (NSCLC). We further demonstrated the use of the assay by monitoring repertoire modulation in a defined model antigen system, cytomegalovirus (CMV). Methods: Peripheral blood mononuclear cells from four healthy donors were challenged with a 1-week exposure to whole-cell lysate from CMV-infected cells or CMVpp65(495-503) peptide (NLVPMVATV). T-cell repertoire perturbations were assessed using the Oncomine TCR Beta-SR Assay and Ion GeneStudio S5 Plus Sequencer. A pp65 tetramer flow cytometry assay was used as an orthogonal method to assess clonal expansion of a subset of CMV-specific T-cells. For evaluation of the assay in peripheral blood lymphocytes from NSCLC donors, five whole blood specimens were evaluated using the same sequencing workflow. Results: The TCR beta assay identified 6,683-61,936 unique clones from 1-2 million reads per sample, and an average of 80% of the total reads were usable for TCR profiling. In the NSCLC donors, TCR convergence and clonality values were consistent with published results and ranged 0.016-0.033 for convergence and 0.09-0.48 for clonality. In the CMV study, TCR sequencing detected the expansion of a common family of clones in all 4 samples in response to antigen stimulation. This expansion corresponded to an increase in pp65 tetramer staining by flow cytometry. Baseline TCR convergence scores ranged 0.009-0.041 and increased 5-fold in one sample as a result of pp65 antigen stimulation. Conclusion: The results of this study demonstrated the utility of profiling of the TCRβ repertoire in a model system and in donors with NSCLC. Additionally, we demonstrated the correlation between RNA-seq methods and protein-tetramer analysis using flow cytometry. These techniques represent an emerging solution that could complement other liquid and tissue diagnostic assays in the clinic and will be of value in predicting host response/resistance and adverse events to immunotherapies. Prospective clinical studies are on-going in which the developed TCR beta assay will undergo further validation.
format Online
Article
Text
id pubmed-8992474
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-89924742022-05-16 Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors Jackson, Leisa P. Tjoa, Benjamin A. Mellert, Hestia Pestano, Gary A. Cancer Drug Resist Original Article Aim: The aim of this study was to demonstrate the utility of T-Cell receptor beta (TCRβ) sequencing as a robust method for assessing T-cell repertoire changes in donors with non-small cell lung cancer (NSCLC). We further demonstrated the use of the assay by monitoring repertoire modulation in a defined model antigen system, cytomegalovirus (CMV). Methods: Peripheral blood mononuclear cells from four healthy donors were challenged with a 1-week exposure to whole-cell lysate from CMV-infected cells or CMVpp65(495-503) peptide (NLVPMVATV). T-cell repertoire perturbations were assessed using the Oncomine TCR Beta-SR Assay and Ion GeneStudio S5 Plus Sequencer. A pp65 tetramer flow cytometry assay was used as an orthogonal method to assess clonal expansion of a subset of CMV-specific T-cells. For evaluation of the assay in peripheral blood lymphocytes from NSCLC donors, five whole blood specimens were evaluated using the same sequencing workflow. Results: The TCR beta assay identified 6,683-61,936 unique clones from 1-2 million reads per sample, and an average of 80% of the total reads were usable for TCR profiling. In the NSCLC donors, TCR convergence and clonality values were consistent with published results and ranged 0.016-0.033 for convergence and 0.09-0.48 for clonality. In the CMV study, TCR sequencing detected the expansion of a common family of clones in all 4 samples in response to antigen stimulation. This expansion corresponded to an increase in pp65 tetramer staining by flow cytometry. Baseline TCR convergence scores ranged 0.009-0.041 and increased 5-fold in one sample as a result of pp65 antigen stimulation. Conclusion: The results of this study demonstrated the utility of profiling of the TCRβ repertoire in a model system and in donors with NSCLC. Additionally, we demonstrated the correlation between RNA-seq methods and protein-tetramer analysis using flow cytometry. These techniques represent an emerging solution that could complement other liquid and tissue diagnostic assays in the clinic and will be of value in predicting host response/resistance and adverse events to immunotherapies. Prospective clinical studies are on-going in which the developed TCR beta assay will undergo further validation. OAE Publishing Inc. 2020-06-18 /pmc/articles/PMC8992474/ /pubmed/35582444 http://dx.doi.org/10.20517/cdr.2020.07 Text en © The Author(s) 2020. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Jackson, Leisa P.
Tjoa, Benjamin A.
Mellert, Hestia
Pestano, Gary A.
Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors
title Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors
title_full Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors
title_fullStr Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors
title_full_unstemmed Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors
title_short Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors
title_sort development of a tcr beta repertoire assay for profiling liquid biopsies from nsclc donors
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992474/
https://www.ncbi.nlm.nih.gov/pubmed/35582444
http://dx.doi.org/10.20517/cdr.2020.07
work_keys_str_mv AT jacksonleisap developmentofatcrbetarepertoireassayforprofilingliquidbiopsiesfromnsclcdonors
AT tjoabenjamina developmentofatcrbetarepertoireassayforprofilingliquidbiopsiesfromnsclcdonors
AT mellerthestia developmentofatcrbetarepertoireassayforprofilingliquidbiopsiesfromnsclcdonors
AT pestanogarya developmentofatcrbetarepertoireassayforprofilingliquidbiopsiesfromnsclcdonors